Abstract
In a nationwide study of 3818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence among COVID-19 deaths, thus not supporting the hypothesis of a clinically relevant involvement of DPP4 inhibition in COVID-19 development and progression.
Keywords: COVID-19; Coronavirus; DPP4; DPP4 inhibitors; Diabetes; Dipeptidyl peptidase 4; SARS-CoV-2.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, coronavirus, diabetes, DPP4, DPP4 inhibitors, Dipeptidyl peptidase 4, 【초록키워드】 SARS-CoV-2, progression, diabetes, DPP4, Dipeptidyl peptidase 4, Prevalence, Patient, inhibitor, Hypothesis, deaths, dipeptidyl peptidase, fatal COVID-19, clinically, diabete, 【제목키워드】 diabetes, Italy, Prevalence, death, inhibitor, diabete,
【저자키워드】 COVID-19, SARS-CoV-2, coronavirus, diabetes, DPP4, DPP4 inhibitors, Dipeptidyl peptidase 4, 【초록키워드】 SARS-CoV-2, progression, diabetes, DPP4, Dipeptidyl peptidase 4, Prevalence, Patient, inhibitor, Hypothesis, deaths, dipeptidyl peptidase, fatal COVID-19, clinically, diabete, 【제목키워드】 diabetes, Italy, Prevalence, death, inhibitor, diabete,
{{{ 추상적인 }}}
치명적인 COVID-19 환자의 차트 3,818개에 대한 전국 연구에서 우리는 DPP4(Dipeptidyl peptidase 4) 억제제 사용의 지리적 차이가 COVID-19 사망 간의 당뇨병 유병률과 상관 관계가 없음을 발견하여 임상적으로 관련성이 있다는 가설을 지지하지 않습니다. COVID-19 개발 및 진행에 DPP4 억제의 관련.
{{ 키워드: }} 코로나19; 코로나바이러스; DPP4; DPP4 억제제; 당뇨병; 디펩티딜 펩티다제 4; 사스 코로나바이러스 2.